We are always evolving in an ever-changing industry.

PrE0403 – Active

Now Open to Enrollment: PrE0403 Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy. NCT03113422